Finerenone, marketed under the brand name Kerendia among others, is a medication used to reduce the risk of kidney function decline, kidney failure, cardiovascular death, non-fatal heart attacks, and hospitalization for heart failure in adults with chronic kidney disease associated with type 2 diabetes. [8]

Jul 23, 2024 · What is finerenone? Finerenone is used in adults with chronic kidney disease related to diabetes mellitus type 2, to reduce the risk of: kidney problems getting worse; a heart attack; needing to be hospitalized for heart failure; or. death from heart failure. Finerenone may also be used for purposes not listed in this medication guide.

Sep 1, 2024 · Data regarding the efficacy and safety of the nonsteroidal mineralocorticoid receptor antagonist finerenone in patients with heart failure and mildly reduced or preserved ejection fraction are...

Oct 23, 2020 · Finerenone, a nonsteroidal, selective mineralocorticoid receptor antagonist, reduced albuminuria in short-term trials involving patients with chronic kidney disease (CKD) and type 2 diabetes....

Finerenone is used to lower the risk of serious kidney and heart problems (eg, kidney function decline, end-stage kidney disease, cardiovascular death, heart attack, and hospitalization for heart failure) in patients with chronic kidney disease associated with type 2 diabetes.

Jun 12, 2024 · Kerendia (finerenone) is commonly used for people who have kidney disease associated with type 2 diabetes. It is used in these people to lower the risk of worsening kidney problems, heart...

Finerenone is in a class of medications called mineralocorticoid receptor (MR) antagonists. It works by blocking the activity of certain steroids made in the body that can damage the heart and kidneys.

Indicated to reduce risk of sustained estimated glomerular filtration rate (eGFR) decline, end-stage kidney disease, cardiovascular death, nonfatal myocardial infarction, and...

Mar 25, 2025 · The Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease (FIDELIO-DKD) trial was a phase 3 study investigating the efficacy and safety of finerenone in 5734 ...

Mar 17, 2025 · Finerenone is the first drug targeting the mineralocorticoid receptor (MR) pathway to demonstrate cardiovascular benefits in a Phase III study in patients with heart failure (HF) with a left ventricular ejection fraction (LVEF) of ≥40%, i.e. mildly reduced or preserved LVEF / Regulatory submission is based on positive results from the Phase II...